

Eric R. Braverman, M.D.

The Place for Achieving Total Health
304 Park Avenue South, 6th Floor, New York, NY 10010

(212) 213-6155
pathmedical@aol.com

EDUCATION

New York University School of Medicine , New York, NY	1983
Doctor of Medicine with honors in Physiology	
Brandeis University , Waltham, MA	1979
B.A., General Science	
Phi Beta Kappa, summa cum laude, honors	

POST-GRADUATE EXPERIENCE

Greenwich Hospital Association , Yale Medical School Affiliate	1983-1984
Massachusetts General Hospital , Harvard Medical School Affiliate	1978-1979

CURRENT INTERESTS

Addiction and substance abuse, neurology, aging and cognitive decline, nutrition, total health and wellness

FACULTY APPOINTMENTS

Weill Cornell Medical College,

Clinical Assistant Professor of Integrative Medicine in Neurological Surgery 2007-2013
Assistant Professor of Integrative Medicine 2012-2013

University of Florida College of Medicine & McKnight Brain Institute, Courtesy

Assistant Professor, Department of Psychiatry (current)

- Under consideration for Director of Obesity and Addiction
- Currently assisting in creation of online anti-aging course
- Hosting American Society of Addiction Medicine Fellow

Cabrini Medical Center, Assistant Attending Physician 2004-2007

New York University Medical School, Instructor in Psychiatry 1995-1996

Helene Fuld Medical Center, Affiliate of Robert Wood Johnson University Hospital,
Consulting staff 1994-1996

CLINICAL ROTATION SUPERVISION (Preceptor to Medical and P. A. Students)

Columbia University School of Medicine

New York University School of Medicine

Rocky Vista University, College of Osteopathic Medicine

Touro College, School of Health Sciences

LICENSES

Florida #ME0067745

New York #159238

Arizona #16127

New Jersey #45071

Pennsylvania #42712

Utah #96-292-390-1205

BOARD MEMBERSHIPS AND OTHER ADVISORY ROLES

American Academy of Anti-Aging Medicine	Life Extension Scientific Advisory Board
American College for the Advancement of Medicine	National Board of Medical Examiners
American College of Nutrition	Pfizer Pharmaceuticals Neuropathic Pain Advisory Board
International Hormone Society	Quantitative EEG Board
Council of Science Editors	

PAST BOARD MEMBERSHIPS AND OTHER ADVISORY ROLES

American Society of Hypertension Inc.	Mensa
Exodus Israel, Family of Comprehensive Addiction Programs	Oasis Mental Retardation Institute
Foundation for the Advancement of Innovative Medicine	Orthomolecular Health-Medicine
George H. Gallup International Institute	Schizophrenia Foundation of New Jersey
International University of Nutrition Education	Secular Organizations for Sobriety (SOS)

CURRENT PROFESSIONAL ORGANIZATIONS

American Academy of Anti-Aging Medicine	American Telemedicine Association
American Academy of Home Care Physicians	Bucks County (PA) Medical Society
American Board of Chelation Therapy	EEG and Clinical Neuroscience Society
American Board of General Practice	International Hormone Society
American College for the Advancement of Medicine	Medical Society of the State of New York
American College of Nutrition	New York County Medical Society
American Medical Association	Quantitative EEG Board
American Neuropsychiatric Association	The American Geriatrics Society
American Public Health Association	The Endocrine Society
American Society of Addiction Medicine	Pharmaceutical Consultant at EISI Corp.
American Society of Bariatric Physicians	

PAST PROFESSIONAL ORGANIZATIONS

Academy of Medicine of New Jersey	Foundation for the Advancement of Innovative Medicine
American Association for the Advancement of Science	International Academy of Preventive Medicine
	Somerset County (NJ) Medical Society

JOURNAL EDITORIAL AND PEER-REVIEW COMMITTEES

Editorial Board Member

Life extension foundation buyers club, Inc. (active)
Neurobiology of Aging (active)
Advances in therapy (active)
Journal of Applied Nutrition (non-active)
Journal of Brain Dysfunction (non-active)
Journal of Reward Deficiency Syndrome (active)
Total Health for Longevity (previously titled Total Health: Body, Mind & Spirit (wrote bi-monthly column) (3 years)
The Physician and Sportsmedicine (active)

Consulting Editor/Reviewer

Biological Psychiatry (active reviewer)
Biological Psychiatry (one editorial)
Journal of Neurotherapy (active)
Journal of Medicinal Plants Research (active)
American Aging Association (active)
PLOS ONE (active)

Assistant Managing Editor

ADHD Journal (2003)

HONORS AND AWARDS

Biomedical Syn. Institute- Wichita, KS.

Outstanding Student Research- \$1,000 Prize for paper titled "Biochemistry of Zinc,"	1978
Outstanding Student Research- \$1,000 Prize for paper titled "Porphyrin Metabolic Pathways,"	1979
<i>Who's Who of Outstanding Men in America</i>	1980
<i>American Medical Association</i>	1986, 1989, 1992, 1995, 1998
Physician's Recognition Award in Continuing Medical Education	
<i>New York College of Podiatric Medicine</i>	2010
Honorary Degree of Doctor of Humane Letters	
Council on Foreign Relations – nominated	2012

GOVERNMENT/COMMUNITY RELATIONS AND ADVISEMENT

American Jewish Committee

Healthy Kids Initiative

New York County Medical Society

New York Public Library, Patron

- Grievance Committee of Peer Review
- CME Committee
- Committee on Public Health
- Managed Care Task Force
- Committee on Government Affairs

New York State Task Force on Life and the Law

Energy Up!

BOOKS

Braverman ER, *What's Your Spiritual Health? Diagnosing This Critical Component of Your Total Health*. New York: Publications for Achieving Total Health (1994).

Braverman ER, *How to Lower Your Blood Pressure and Reverse Heart Disease Naturally*. New York: Publications for Achieving Total Health (1995).

Braverman ER, Taub M. *Hypertension and Nutrition*. New York: McGraw Hill (1996).

Braverman ER, *The Healing Nutrients Within: Facts, Findings and New Research on Amino Acids*. New Canaan, CT: Keats Publishing (1997).

Braverman ER, *PATH Wellness Manual*, 2nd ed., New York: Publications for Achieving Total Health (1998).

Braverman ER, *Male Sexual Fitness. Causes and Solutions for Andropause*. Lincolnwood, IL: Keats Publishing (1999).

Braverman ER, *The Healing Nutrients Within: Facts, Findings and New Research on Amino Acids. 3rd Edition*. Laguna Beach, CA: Basic Health Publications, Inc. (2003).

Braverman ER, *The Edge Effect: Achieve Total Health and Longevity with the Balanced Brain Advantage*. New York, NY: Sterling Publishing (2004).

Braverman ER, *The Amazing Way to Reverse Heart Disease Naturally*. North Bergen, NJ: Basic Health Publications, Inc. (2004).

Braverman ER, *Younger You: Unlock the Hidden Power of Your brain to Look and Feel 15 Years Younger*. New York: McGraw-Hill (2007).

Braverman ER, *Younger (Thinner) You Diet: How Understanding Your Brain Chemistry Can Help You Lose Weight, Reverse Aging, and Fight Disease*. New York: Rodale Inc. (2009).

Braverman ER, *Younger (Sexier) You: Look and Feel 15 Years Younger by Having the Best Sex of Your Life*. New York: Rodale Inc. (2011).

Braverman ER, *Younger Brain, Sharper Mind: A 6-Step Plan for Preserving and Improving Memory and Attention at Any Age from America's Brain Doctor*, New York: Rodale, Inc. (2011).

BOOK CHAPTERS

Pfeiffer CC, Braverman ER. Folic acid and vitamin B12 therapy for the low histamine, high copper biotype of schizophrenia. In: Botez M, Reynold H, eds. *Folic Acid in Neurology, Psychiatry and Internal Medicine*. New York: Raven Press; 1979: 483-487.

Braverman ER. Behavior pathologies: Pharmacology of acute and chronic amino acid supplementation: Clinical implications. In W.B. Essman, ed., *Nutrients and Brain Function*. Basel: S.

Karger AG; 1987.

Blum K, Braverman ER, et al. Neurogenetics of compulsive disease: Neuronutrients as adjuncts to recovery. In Wallace BC, ed. *The Chemically Dependent: Phases of Treatment and Recovery*. New York: Brunner/Mazel Inc.; 1992: 187-231.

Blum K, Sheridan PJ, Chen TJH, Wood RC, Braverman ER, et al. The dopamine D2 receptor gene locus in reward deficiency syndrome: Meta analyses. In: Blum K, Noble EP, eds. *Handbook of Psychiatric Genetics*. Boca Raton, FL: CRC Press; 1997: 407-434.

Blum K, Cull JG, Braverman ER, Chen TJH, Comings DE. Reward deficiency syndrome: Neurobiological genetic aspects: In Blum K, Noble EP, eds. *Handbook of Psychiatric Genetics*. Boca Raton, FL: CRC Press; 1997: 311-332.

Braverman ER. Neurological and psychological etiologies and brain revival in the general office setting. In: Goldman RM, Klatz R, eds. *Anti-Aging Medical Therapeutics: Volume 2*. 1998: 70-77.

Braverman ER. Clinical utilization of positron emission tomography (PET) scanning in the anti-aging practice. In: Goldman RM, Klatz R, eds. *Anti-Aging Medical Therapeutics: Volume 3*. 1999: 90-94.

Blum K, Fornari F, Downs BW, Waite RL, Giordano J, Smolen A, Lui Y, Tain J, Majmundr N, Braverman ER. Genetic Addiction Risk Score (GARS): Testing for Polygenetic Predisposition and Risk for Reward Deficiency Syndrome (RDS). In C. King (Ed.) *Gene Therapy Applications*: 327-362.

Blum K, Oscar-Berman M, Gardner EL, Simpatico T, Braverman ER, Gold MS. Neurogenetics & Neurobiology of Dopamine in Anhedonia. In: *Anhedonia: A Comprehensive Handbook* (vol 1). Editor: Ritsner M. Chapter 9: Springer, London, 2014, pp. 179-208.

HANDBOOKS

Blum K, Holder J (in collaboration with Cull JG, Chen THJ, Braverman ER.) *Handbook of Abusable Drugs*, Amended Edition, Mattituck, NY: Amereon Press (1997).

Braverman ER, Watt TJ, Bajaj A. *Cognitive disease & impairments: Diagnostics, prevention, and therapeutic interventions. Health Practitioner's Guide to Anti-Aging & Regenerative Medicine* 1st Edition. American Academy of Anti-Aging Medicine (2009).

PEER-REVIEWED PUBLICATIONS

1. Braverman ER. Orthomolecular medicine and megavitamin therapy: Future and philosophy. *The American Journal of Orthopsychiatry*. 1979; 3(4): 265-272.
2. Braverman ER, Pfeiffer CC. Essential trace element and cancer. *The American Journal of Orthomolecular Psychiatry*. 1982; 11(1): 28-40.
3. Pfeiffer CC, Braverman ER. Zinc, The brain and behavior. *Biological Psychiatry*. 1982; 17(4): 513-

- 534.
4. Braverman ER, Pfeiffer CC. Suicide and biochemistry. *Biological Psychiatry*. 1985; 20(2): 123-124.
 5. Braverman ER, Lamola S, Pfeiffer CC. Pharmacology of chronic supplementation of amino acids. *Journal of Clinical Pharmacology*. 1985; 25: 455-474.
 6. Braverman ER, Lamola S. Acute and chronic supplementation of amino acids. *Journal of Orthomolecular Medicine*. 1986, 50-56.
 7. Braverman ER. T-cell ratios: Modulation by nutrition. *Journal of Orthomolecular Medicine*. 1987; 2(1): 46-49.
 8. Braverman ER, Iovovich B. Nutrient profile of hypothermic. *Journal of Orthomolecular Medicine*. 1987; 2(3): 191-193.
 9. Braverman ER, Weissberg E. Elevated IgE levels in patients with low whole blood histamine. *Journal of Orthomolecular Medicine*. 1987; 2(4) 219-220.
 10. Braverman ER, Weissberg E. Fish oil as one therapy in cardiovascular risk factor reduction. *Journal of Orthomolecular Medicine*. 1988; 3(1): 6-10.
 11. Braverman ER, Rayner H. Plasma fatty acids in HTN patients before and after EPA supplements. *Journal of the American Society of Hypertension*. 1988.
 12. Braverman ER. Medical history and the holistic perspective. *Journal of Orthomolecular Medicine*. 1988; 3(4) 191-196.
 13. Braverman ER, Sohler A, Pfeiffer CC. Cesium chloride: Preventive medicine for radioactive cesium exposure. *Medical Hypothesis*. 1988; 26:93-95.
 14. Braverman ER. Memories of Carl C. Pfeiffer, MD, PhD, physician, scientist, teacher, and philanthropist. *Journal of Orthomolecular Medicine*. 1989; 4(1): 5-7.
 15. Shafer R, Braverman ER. Q fever endocarditis: Delay in diagnosis due to an apparent clinical response to corticosteroids. *American Journal of Medicine*. 1989; 86: 729.
 16. Braverman ER. Phenylketonuria in an 8-year-old hyperactive child. *Pediatrics*. 1989; 2:217-218.
 17. Braverman ER. Remission of forty years of headaches with Divalproex Sodium. *Brain Dysfunction*. 1989; 2:55.
 18. Braverman ER, Smith R, Smayda R, Blum K. Modification of P300 amplitude and other electrophysiological parameters of drug abuse by cranial electrical stimulation. *Current Therapeutic Research*. 1990; 48:586-596.
 19. Braverman ER, Blum K, Smayda R. A commentary on brain mapping in 60 substance abusers: Can the potential for drug abuse be predicted and prevented by treatment? *Current Therapeutic Research*. 1990; 48:569-585.
 20. Braverman ER. Brain mapping: A short guide to interpretation, philosophy and future. *Journal of Orthomolecular Medicine*. 1990; 5:1-12.
 21. Braverman ER. Brain electrical activity mapping in treatment resistant schizophrenics. *Journal of Orthomolecular Medicine*. 1990; 5:46-48.
 22. Braverman ER. Fish oil lowers fibrinogen. *Journal of Applied Nutrition*. 1990; 42.
 23. Rayner H, Lovelle S, Braverman ER. Nutrition and wound healing. *Journal of Orthomolecular Medicine*. 1991; 31-43.
 24. Braverman ER. Olfactory hallucinations remit with Alprazolam: Usefulness of brain mapping in diagnosis. *Journal of Orthomolecular Medicine*. 1991; 6:110-111.

25. Braverman ER. Reversal of pre-leukemia with antioxidants. *Journal of Nutritional Medicine*. 1991; 313-315.
26. Braverman ER, Swartz, K. Cranial electrotherapy stimulation. *Townsend Letter for Doctors*. 1991; 101: 1045.
27. Braverman ER. Sports and exercise: Nutritional augmentation and health benefits. *Journal of Orthomolecular Medicine*. 1991; 6:191-201.
28. Braverman ER, Smayda, RJ. Chronic lead poisoning as a cause of bulimia: Hair analysis and brain electrical activity mapping (BEAM) as diagnostic aid. *Journal of Orthomolecular Medicine*. 1992; 7:53-55.
29. Braverman ER, Swartz K, Blum K, Moss R. Electrotherapy for addictions. *Addiction and Recovery*. 1992; 34-36.
30. Braverman ER, Weissberg E. Nutritional treatments for hypertension. *Journal of Orthomolecular Medicine*. 1992; 7: 221-244.
31. Braverman ER. Brain electrical activity mapping (BEAM) in patients who commit violent crimes: Are bitemporal abnormalities a characteristic? *Journal of Orthomolecular Medicine*. 1993; 8: 154-156.
32. Blum K, Braverman ER, Dinardo M, Wood R, Sheridan P. Prolonged P300 latency in a neuropsychiatric population with the D2 dopamine receptor A1 allele. *Pharmacogenetics*. 1994; 4: 313-322.
33. Blum K, Sheridan P, Wood R, Braverman ER, et al. Dopamine D2 receptor gene variants association and linkage studies in impulsive-addictive-compulsive behavior. *Pharmacogenetics*. 1995; 5: 122.
34. Blum K, Wood RC, Braverman ER, Chen TJH, Sheridan PJ. The D2 dopamine receptor gene as a predictor of compulsive disease: Baye's theorem. *Functional Neurology*. 1995; 10(1): 37-44.
35. Blum K, Braverman ER, Wood RC, Sheridan PJ. Increased prevalence of the Taq 1 A1 allele of the dopamine D2 receptor gene in obesity with comorbid polysubstance abuse. *Pharmacogenetics*. 1995; 6: 297-305.
36. Blum K, Sheridan PJ, Wood RC, Braverman ER, et al. Dopamine D2 receptor gene variants: association and linkage studies in impulsive-addictive-compulsive behavior. *Pharmacogenetics*. 1995; 5:121-141.
37. Blum, K, Sheridan, PJ, Wood, R, Braverman, ER. Dopamine D2 receptor gene polymorphisms in Scandinavian chronic alcoholics: A reappraisal. *Eur. Arch. Psychiatry Clin. Neuroscience*. 1995; 244: 50-52.
38. Blum K, Sheridan P, Wood RC, Braverman ER, Chen TJH, Comings DE. Dopamine D2 receptor gene variants: association and linkage studies in impulsive-addictive-compulsive behavior. *Pharmacogenetics and Genomics*. 1995; 5: 121-141.
39. Braverman ER, Cumings E, Cull G, Blum K. Reward Deficiency Syndrome. *American Scientist*, 1996; 84: 132-145.
40. Blum K, Sheridan PJ, Braverman ER, et al. The D2 dopamine receptor gene as a determinant of reward deficiency syndrome. *Journal of the Royal Society of Medicine*. 1996; 89(7): 396-400.
41. Braverman ER, Blum K. Substance use disorder exacerbates brain electrophysiological abnormalities in a psychiatrically-ill population. *Clinical Electroencephalography*. 1996; 27(S4): 5-27.

42. Braverman E, Blum K. Comorbid psychiatric disorders in a holistic health clinic. *Society of Medicine*. 1996; 89.
43. Blum K, Sheridan PJ, Wood RC, Braverman ER, et al. The D2 dopamine receptor gene as a predictor of impulsive-addictive-compulsive behavior: Bayes' theorem. *Journal of the Royal Society of Medicine*. 1996; 89: 396-400.
44. Blum K, Braverman ER, Cull JG, et al. Polymorphism of the dopamine D2 receptor gene associates with brain electrophysiological abnormalities in humans: Exacerbation with substance use disorder. *Clinical Electroencephalography*. 1996.
45. Braverman ER, Blum, K. Substance use disorder exacerbates brain electrophysiological abnormalities in a psychiatrically-ill population. *Clinical Electroencephalography*. 1996; 27(4): 5-28.
46. Blum K, Braverman ER, Wu S, et al. Association of polymorphisms of dopamine D2 receptor (DRD2) and dopamine transporter (DAT1) genes with schizoid/avoidant behaviors (SAB). *Molecular Psychiatry*. 1997; 2: 239-246.
47. Blum K, Cull JG, Chen TJH, Garcia-Swan Susan, Holder JM, Wood R, Braverman ER, et al. Clinical evidence for effectiveness of Phencal in maintaining weight loss in an open label controlled 2 year study. *Current Therapeutic Research*. 1997; 58(10): 745-763.
48. DeFrance, JF, Hymek, C, Trachtenberg, MC, Ginsberg, LD, Schweitzer, FC, Estes, S, Chen, TJ, Braverman, ER, et al. Enhancement of attention processing by Kantroll in healthy humans: A pilot study. *Clinical Electroencephalography*. 1997; 28(2):68-75.
49. Blum, K, Kaats, G, Eisenberg, A, Sherman, M, Davis, K, Comings, D, Cull, J, Chen, THJ, Wood, R, Bucci, L, Wise, J, Braverman ER. Chromium picolinate induces changes in body composition as a function of the Taq1 Dopamine D2 Receptor A2 Alleles. *Journal of American College of Nutrition*. 1998.
50. Braverman ER, Querijero M. Brain aging and diagnostic testing. *International Journal of Anti-Aging Medicine*. 2000.
51. Blum K, Braverman E, Holder J, et al. Reward deficiency syndrome: A biogenetic model for the diagnosis and treatment of impulsive, addictive and compulsive behaviors. *Journal of Psychoactive Drugs*. 2000; 32(Suppl: i-iv): 1-112.
52. Blum K, Braverman ER. Reward Deficiency Syndrome: An emerging concept. *Molecular Psychiatry*. 2001; 6(Suppl1): S3.
53. Braverman ER, Blum K, Lubar JF, Lubar JO, Comings E. Genetic dopaminergic deficits: Clinical correlates to schizoid/avoidant personality, ADHD probands, pathological violence, P300 event related potential and TOVA attention test. *Molecular Psychiatry*. 2001; 6(Suppl1): S5.
54. Braverman ER, Smith D. A medical model for "Reward Deficiency Syndrome": clinical significance of genetic dopamine deficiencies. *Molecular Psychiatry*. 2001; 6(Suppl. 1): S6-S8.
55. Braverman ER, Blum K. P300 and Wechsler memory scores on an aging large population of patients. *Clinical Electroencephalography*. September 11, 2002.
56. Blum K, Braverman ER. Reward deficiency syndrome: A biogenetic model for the treatment of impulsive, addictive, and compulsive behaviors. *Journal of Psychoactive Drugs*. 2001; 32:1-12.
57. Blum K, Braverman ER. Reward deficiency syndrome: An emerging concept. *Molecular Psychiatry*. 2001; 6:S3.
58. Blum K, Chen TJH, Blum SH, Downs BW, Braverman ER, Foster JF, Meshkin B. Nutrigenomics and pharamcogenomics: a scientific wonderland. *Social Science Information*. 2006;

- 45(1):35-52.
59. Blum K, Chen TJH, Blum SH, Comings DE, Mengucci JF, Meshkin B, Downs BW, Braverman ER. Reward Deficiency Syndrome (RDS): Neurogenetic aspects of aging and related behavioral disorders specific to dopaminergic pathways. *Anti-Aging Therapeutics*. 2006; 8: 9-26.
 60. Holder, JM, Duncan, RC, Gissen, M, Miller, M, Braverman, ER, Blum, K. Increasing retention rates among the chemically dependent in residential treatment: Auriculotherapy and sublaxation-based chiropractic care. *Molecular Psychiatry*. 2001; 6(S8).
 61. Braverman E, Blum K. P300 (Latency) event related potential: An accurate predictor of memory impairment. *Clinical Electroencephalography*. 2003; 34(3).
 62. Braverman E, Blum K, Stanford M. From brain science to brain based medicine. *Medical Hypotheses*. 2004; 63(5): 919-920.
 63. Chen, TJH, Blum, K, Payte, JT, Schoolfield, J, Hopper, D, Stanford, M, Braverman, ER. Narcotic antagonists in drug dependence: Pilot study showing enhancement of compliance with amino acid and enkephalinase inhibition therapy. *Medical Hypotheses*. 2004; (63)3: 538-548.
 64. Chen JHT, Blum K, Mathews D, Fisher L, Schnautz N, Braverman ER, et al. Are dopaminergic genes involved in a predisposition to pathological aggression? Hypothesizing the importance of "super normal controls" in psychiatric genetic research of complex behavioral disorders. *Medical Hypotheses*. 2005; 65(4): 703-707.
 65. Braverman ER, Rayannavar A, Makhija N, et al. Delayed P300 latency correlates with abnormal test of variables of attention (TOVA) in adults and predicts early cognitive decline in a clinical setting. *Advances in Therapy*. 2006; 23(4): 65.
 66. Blum K, Chen T, Meshkin B, Downs WB, Gorden C, Blum S, Braverman ER, et al. Reward deficiency syndrome in obesity: A preliminary cross-sectional trial with a genotrim variant. *Advances in Therapy*. 2006; 23 (6): 1040-1051.
 67. Blum K, Chen TJH, Blum SH, Comings DE, Mengucci JF, Meshkin B, Downs BW, Braverman ER. Reward deficiency syndrome (RDS): Neurogenetic aspects of aging and related behavioral disorders specific to dopaminergic pathways. *Anti-Aging Therapeutics*. 2006; 8: 9-26.
 68. Blum K, Chen, TJ, Meshkin B, Downs WB, Gordon, CA, Blum S, Mengucci JF, Braverman ER, et al. Genotrim a DNA-customized nutrigenomic product, targets genetic factors of obesity: Hypothesizing a dopamine-glucose correlation demonstrating reward deficiency syndrome (RDS). *Medical Hypotheses*. 2006; 68(4): 844-852.
 69. Chen T, Blum K, Waite R, Meshkin B, Schoolfield J, Downs WB, Braverman ER, et al. Reward deficiency syndrome (RDS) and substance use disorder (S.U.D.): The gene narcotic attenuation program (GNAP) including haveos** (synaptamine) attenuates addictive related behaviors. *Advances in Therapy*. 2007; 24(2): 402-414.
 70. Braverman ER, Chen TJH, Sonntag W, et al. Low human plasma levels of sex hormones and human growth factors(s) correlate to cognitive decline marked by prolonged P300 latency as a function of gender in a clinical setting: A paradigm shift. *Journal of the American Aging Association*. 2007.
 71. Blum K, Chen T, Meshkin B, Waite R., Dinublie N, Smith T, Callahan M, Prihoda T, Schoolfield J, Downs W, Arcuri V, Braverman ER, et al. Reward gene polymorphisms may predict high rates of injury and addiction in the workforce: A theoretical review. *International Journal of Law & Psychiatry*.

72. Chen T, Blum K, Kaats G, Braverman ER, et al. Chromium Picolinate (CrP) a putative anti-obesity nutrient induces changes in body composition as a function of the Taq1 dopamine D2 receptor polymorphisms in a randomized double-blind placebo controlled study. *Gene Therapy and Molecular Biology*. 2007; 11: 161-170.
73. Blum K, Chen TJH, Meskin B, Downs BW, Waite RL, Braverman ER, et al. Pharmacogenomic & nutrigenomic aspects of neurobesigenics, a genetic pleiotropic clinical subtype of Reward Deficiency Syndrome (RDS). *Current Pharmacogenomics*.
74. Blum K, Chen TJH, Meshkin B, Waite RL, Downs BW, Blum SH, Mengucci JF, Arcuri V, Braverman ER, et al. Manipulation of Catechol-O Methyl Transferase (COMT) activity to influence the attenuation of substance seeking behavior, a subtype of Reward Deficiency Syndrome (RDS), is dependent upon gene polymorphisms: A hypothesis. *Medical Hypotheses*. 2007; 69(5): 1054-60.
75. Blum K, Chen TJH, Downs BW, Meshkin B, Blum SH, Martinez Pons M, Mengucci JF, Waite RL, Arcuri V, Varshafski M, Braverman ER. Synaptamine (SG8839) an amino-acid enkephalinase inhibition nutraceutical improves recovery of alcoholics, a subtype of Reward Deficiency Syndrome (RDS). *Trends in Applied Sciences Research*. 2007; 2(2): 132-138.
76. Blum K, Chen TJH, Meshkin B, Blum SH, Mengucci JF, Waite RL, Arcuri V, Braverman ER. The PPARgamma Pro12Ala allele polymorphism of the Peroxisome Proliferator-Activated Receptor (gamma) Gene (PPARG2) is a risk factor with a self-identified obese Dutch Population. *Gene Therapy & Molecular Biology*. 2007; 11(1); 37-42.
77. Chen TJH, Blum K, Mathews D, Fisher L, Schnautz N, Braverman ER, et al. Preliminary association of both the Dopamine D2 Receptor (DRD2) [Taq1 A1 Allele] and the Dopamine Transporter (DAT1) [480 bp Allele] genes with pathological aggressive behavior, a clinical subtype of Reward Deficiency Syndrome (RDS) in adolescents. *Gene Therapy and Molecular Biology*. 2007; 11(1): 93-112.
78. Chen TJH, Blum K, Kaats G, Braverman ER, et al. Reviewing the role of putative candidate genes in "Neurobesigenics," a clinical subtype of Reward Deficiency Syndrome (RDS). *Gene Therapy and Molecular Biology*. 2007; 11(1): 61-74.
79. Braverman ER, Chen T, Prihoda T, et al. Plasma growth hormones, P300 event-related potential and test of variables of attention (T.O.V.A) are important neuroendocrinological predictors of early cognitive decline in clinical setting: Evidence supported by structural equation modeling parameter estimates. *Age*. 2007; 29(2-3): 55-67.
80. Blum, K, Chen, AL, Chen, TJ, Prihoda, TJ, Schoolfield, J, DiNubile, N, Waite, RL, Arcuri, V, Kerner, M, Braverman, ER, et al. The H-Wave Device is an effective and safe non-pharmacological analgesic for chronic pain: A meta-analysis. *Advances in Therapy*. 2008; 25(7): 644-57.
81. Chen AL, Chen TJ, Braverman ER, et al. Hypothesizing that marijuana smokers are at a significantly lower risk of carcinogenicity relative to tobacco-non-marijuana smokers: Evidenced based on statistical reevaluation of current literature. *Journal of Psychoactive Drugs*. 2008; 40(3): 263-72.
82. Blum K, Chen AL., Chen TJ, Rhoades P, Prihoda TJ, Downs BW, Waite RL, Williams L, Braverman ER, et al. LG839: Anti-obesity effects and polymorphic gene correlates of Reward Deficiency Syndrome. *Advances in Therapy*. 25 (9): 894-913, 2008.

83. Blum K, Chen TJH, Williams L, Chen ALC, Downs WB, Waite RL, Huntington T, Sims S, Prihoda T, Rhoads P, Reinking J, Braverman D, Kerner M, Blum SH, Quirk B, Braverman ER. A short term pilot open label study to evaluate efficacy and safety of LG839, a customized DNA directed nutraceutical in obesity: Exploring Nutrigenomics. *Gene Therapy and Molecular Biology*. 2008; 12: 371-382.
84. Blum K, Chen ALC, Chen TJH, Rhoades P, Prihoda TJ, Downs BW, Bagchi D, Bagchi M, Blum SH, Williams L, Braverman ER, et al. Dopamine D2 Receptor Taq A1 allele predicts treatment compliance of LG839 in a subset analysis of pilot study in the Netherlands. *Gene Therapy and Molecular Biology*. 2008; 12: 129-140.
85. Chen ALC, Blum K, Chen TJH, Reinking J, Waite RL, Downs BW, Braverman ER, et al. The impact of biomimics technology and DNA directed anti-obesity targeting of the brain reward circuitry. *Gene Therapy and Molecular Biology*. 2008; 12: 45-68.
86. Meshkin B, Chen TJH, Chen ALC, Prihoda TJH, Morrisette H, Braverman ER, et al. Health economics of nutrigenomics in weight management. *Gene Therapy and Molecular Biology*. 2008; 12: 25-30.
87. Blum K, Ho CK, Chen ALC, Fulton M, Fulton B, Westcott WL, Reinl G, Braverman ER, et al. Electrotherapeutic devices in sports injuries. *The Physician and Sportsmedicine*. 2008.
88. Blum K, Ho CK, Chen LC, Fulton M, Fulton B, Westcott WL, Reinl G, Braverman ER, et al. The H-Wave Device induces NOdependent augmented microcirculation and providing both analgesia and tissue healing in sports injuries. *The Physician and Sportsmedicine*. 2008; 36(1): 103-114.
89. Blum K, Downs WB, Chen ALC, Chen TJH, Waite RL, Braverman ER, et al. A trieste on nutrigenomic targeting of overall wellness and carbohydrate craving behavior. The Genetic Positioning System (GPS) Map. *PLOS Medicine*. 2008.
90. Braverman ER. The path to life extension executive health program. *Anti- Aging Therapeutics*. 2008.
91. Blum K, Chen AL, Chen TJ, Braverman ER, et al. Activation instead of blocking mesolimbic dopaminergic reward circuitry is a preferred modality in the long term treatment of Reward Deficiency Syndrome (RDS): a commentary. *Theoretical Biology and Medical Modeling*. 2008; 12(5): 24.
92. Downs WB, Chen ALC, Chen TJH, Waite RL, Braverman ER, et al. Nutrigenomic targeting of carbohydrate craving behavior: Can we manage obesity and aberrant craving behaviors with neurochemical pathway manipulation by immunological compatible substances (nutrients) using a genetic positioning system (GPS) Map? *Medical Hypotheses*. 2009; 73(3): 427-434.
93. Chen AL, Chen TJ, Waite RL, Reinking J, Tung HL, Rhoades P, Downs BW, Braverman ER, et al. Hypothesizing that brain reward circuitry genes are genetic antecedents of pain sensitivity and critical diagnosis and pharmacogenomic treatment targets for chronic pain conditions. *Medical Hypotheses*. 2009; 72(1): 14-22.
94. Blum K, Chen ALC, Braverman ER, et al. Attention-Deficit-Hyperactivity Disorder and Reward Deficiency Syndrome. *Neuropsychiatric Disease and Treatment*. 2009; 4(5): 893-918.
95. Blum K, Chen ALH, Chen TJH, Downs BW, Braverman ER, et al. Healing enhancement of chronic venous stasis ulcers utilizing H-Wave Device therapy: A case series. *BMC Research Notes*. 2009.

96. Blum K, Chen ALC, Chen TJH, Waite LR, Downs BW, Braverman ER, et al. Chronic H-Wave(R) device stimulation and program induces significant increases in the range of motion of postoperative rotator cuff reconstruction in a double-blinded randomized placebo controlled human study. *BMC Musculoskeletal Disorders*. 2009; 10: 132.
97. Braverman ER, Chen TJH, Chen ALC, et al. Age-related increases in parathyroid hormone may be antecedent to both osteoporosis and dementia. *BMC Endocrine Disorders*. 2009; 9(1): 21.
98. Blum K, Chen TJH, Chen, ALC, Prihoda, TJ, Waite RL, Williams L, Downs BW, Kerner M, Braverman ER. A randomized double blind, placebo controlled investigation of the anti-anxiety effects of Synaptamine Complex™, a putative dopaminergic activator: Hypothesizing a targeted psychodermatological nutraceutical to reduce stress and improve dermatologic conditions. *Journal of Psychosocial Science*. 2009.
99. Blum K, Chen TJH, Chen ALH, Bowirrat A, Downs BW, Waite RL, Reinking J, Kerner M, Braverman D, DiNubile N, Rhoades P, Braverman ER, et al. Genes and Happiness. *Gene Therapy and Molecular Biology*. 2009; 13: 92-129.
100. Blum K, Chen AL, Chen TJH, Bowirrat A, Waite RL, Kerner M, Blum SH, Downs BW, Savarimuthu S, Rhoades P, Reinking J, Braverman ER, et al. Putative targeting of Dopamine D2 Receptor function in Reward Deficiency Syndrome (RDS) by Synaptamine Complex™ Variant (KB220): Preliminary clinical trial showing anti-anxiety effects. *Gene Therapy and Molecular Biology*. 2009; 13: 214-230.
101. Blum K, Chen AL, Chen TJH, Bowirrat A, Waite RL, Prihoda TJ, Blum SH, Downs BW, Kerner M, Savarimut S, Rhoades P, Reinking J, Braverman ER, et al. An in-patient randomized, double-blind, placebo controlled investigation of the anti-anxiety effects of the Nutraceutical Synaptamine Complex™: Putative targeting of Dopamine D2 Receptor function in Reward Deficiency Syndrome (RDS). *Journal of Nutrition*. 2009.
102. Blum K, Chen THJ, Tucker D, Graham NA, Chen ALH, Bowirrat A, Morse SA, Giordano J, Madigan M, Downs BW, Braverman ER. Depressed dopamine function in Attention-Deficit/Hyperactivity Disorder: Should genotyping of dopaminergic and other gene polymorphisms constitute early diagnosis in children. *Journal Psychiatry & Neuroscience*. 2009.
103. Blum K, Chen TJH, Downs BW, Bowirrat A, Waite RL, Braverman ER, et al. Neurogenetics of dopaminergic receptor supersensitivity in activation of brain reward circuitry and relapse: Proposing “Deprivation-Amplification Relapse Therapy” (DART). *Postgraduate Medicine*. 2009; 121(6): 176-196.
104. Braverman ER, Chen TJH, Martinez-Pons M, et al. Age dependent brain processing speed as measured by prolonged P300 latency is associated with increased parathyroid subclinical hyperparathyroidism, an age dependent phenomena, as an antecedent of both osteoporosis and dementia. *Clinical Endocrinology & Metabolism*. 2009.
105. Braverman ER, Chen TJH, Chen ALH, et al. Preliminary investigation of plasma levels of sex hormones and human growth factor (s), and P300 latency as correlates to cognitive decline as a function of gender. *BMC Research Notes*. 2009; 2(1):126.
106. Blum K, Chen TJH, Downs B, Williams, Chen AJH, Bowirrat A, Waite RL, Braverman ER, et al. Dopamine amplified activation of reward and relapse as a function of post-junctional denervation supersensitivity of Dopamine D2 (A1 allele) Receptor deficiency: Proposing Deprivation-Amplification Relapse Therapy (DART). *Theoretical Biology and Medical Modeling*.

- 2009.
107. Braverman ER, Chen ALC, Chen TJH, et al. Test of Variables of Attention (TOVA) as a predictor of early attention complaints, an antecedent to dementia. *Neuropsychiatric Disease, Diagnosis and Treatment*. 2010; 6: 681-690.
 108. Blum K, Giordano J, Morse S, Liu Y, Tan J, Bowirrat A, Smolen A, Waite R, Downs W, Madigan M, Kerner M, Fornari F, Stice E, Braverman ER, et al. Genetic Addiction Risk Score (GARS) analysis: exploratory development of polymorphic risk alleles in poly-drug addicted males. *The IIOAB Journal*. 2010; 1(2).
 109. Blum K, Chen TJH, Chen ALH, Downs BW, Waite RL, Reinkin J, Kerner M, Braverman D, DiNubile N, Rhoades P, Braverman ER. Are Human Nature Genes Tied to Happiness? *Gene Therapy and Molecular Biology*. 2009; 13:91-129.
 110. Blum K, Chen TJH, Williams L., Chen ALC, Downs WB, Waite RL, Huntington T, Sims S, Prihoda T, Rhoads P, Reinking J, Braverman D, Kerner M, Blum SH, Quirk B, Braverman ER. A short-term pilot open label study to evaluate efficacy and safety of LG839, a customized DNA directed nutraceutical in obesity: Exploring nutrigenomics. *Gene Therapy and Molecular Biology*. 2008; 12: 301-312.
 111. Braverman ER, Bowirrat A, Damle UJ, et al. Adult Growth Hormone deficiency treatment with a combination of growth hormone and insulin-like growth factor-1 resulting in elevated sustainable insulin-like growth factor-1 and insulin-like growth factor binding protein 3 plasma levels: a case report. *Journal of Medical Case Reports*. 2010; 15(4):305.
 112. Blum K, Chen TJH, Chen ALH, Madigan M, Downs BW, Waite RL, Braverman ER, et al. Do dopaminergic gene polymorphisms affect mesolimbic reward activation of music listening response? Therapeutic impact on Reward Deficiency Syndrome (RDS). *Medical Hypothesis*. 2010; 74(3): 513-20.
 113. Blum K, Chen TJH, Morse S, Giordano J, Chen AL, Thompson J, Allen C, Smolen A, Lubar J, Stice E, Downs WB, Waite RL, Madigan MA, Kerner M, Fornari F, Braverman ER. Overcoming qEEG abnormalities and reward gene deficits during protracted abstinence in male psychostimulant and polydrug abusers utilizing putative dopamine D2 agonist therapy: Part 2. *Postgraduate Medicine*. 2010; 122(6):214-226.
 114. Bowirrat A, Chen TJH, Blum K, Madigan M, Bailey J, Lih CCA, William DB, Braverman ER et al. Neuro-psychopharmacogenetics and neurological antecedents of Posttraumatic Stress Disorder: Unlocking the mysteries of resilience and vulnerability. *Current Neuropharmacology*. 2010; 8(4): 335-358.
 115. Braverman ER, Braverman D, Arcuri V, Kerner M, Downs W, Blum K. Sustainable weight loss and muscle gain utilizing the rainbow diet, targeting noradrenergic and dopaminergic mechanistic sites, hormonal deficiency repletion therapy and exercise: A case report. *The Bariatrician*. 2010; 25(2):18-28.
 116. Blum K, Giordano J, Morse S, Bowirrat A, Madigan M, Downs W, Waite R, Kerner M, Damle U, Braverman ER, et al. Understanding the high mind: Humans are still evolving genetically. *The IIOAB Journal*. 2011; 2 (2):1-22.
 117. Westcott WL, Chen T, Neric FB, DiNubile N, Bowirrat A, Madigan M, Downs BW, Giordano J, Morse S, Chen ALC, Bajaj A, Kerner M, Braverman ER et al. The Marc Pro™ device improves

- muscle performance and recovery from concentric and eccentric exercise induced muscle fatigue in humans: A Pilot Study. *Journal of Exercise and Physiology Online*. 2011; 14(2): 55-67.
118. Dinubile N, Westcott W, Reinl G, Bajaj A, Braverman ER, Madigan M, Giordano J, Blum K. Marc Pro™ Device a Novel Paradigm Shift in Muscle Conditioning, Recovery And Performance: Induction of Nitric Oxide (NO) Dependence Enhanced Microcirculation Coupled with Angiogenesis Mechanisms. *Journal of Exercise Physiology*. 2011; 14(5).
119. Chen TJH, Blum K, Chen ALC, Bowirrat A, Downs WB, Madigan MA, Waite RL, Bailey JA, Kerner M, Yeldandi S, Majmundar N, Giordano J, Morse S, Miller D, Fornari F, Braverman ER. Neurogenetics and clinical evidence for the putative activation of the brain reward circuitry by a Neuroadaptogen: Proposing an addiction candidate gene panel map.” *Journal of Psychoactive Drugs*. 2011; 43(2): 108-127.
120. Blum K, Bailey J, Femino J, Simpatico T, Morse S, Giordano J, Damle U, Kerner M, Braverman ER, et al. Can the chronic administration of the combination of buprenorphine and naloxone block dopaminergic activity causing anti-reward and relapse potential? *Journal of Molecular Neurobiology*. 2011; 44(3): 250-68,
121. Blum K, Bowirrat A, Downs BW, Waite RL, Giordano J, Morse S, Madigan M, Downs JM, Braverman ER, Polanin M, Simpatico T. “Nutrigenomics of Neuradaptogen Amino-Acid-Therapy (NAAT): Overcoming Carbohydrate Bingeing and Overeating Through Neurometabolic Mechanisms.” *Function Foods in Health and Disease*. 2011: 1(9): 310-378.
122. Blum K, Braverman ER, et al. “Hypothesizing Synergy between Acupuncture/Auriculotherapy and Natural Activation of Mesolimbic Dopaminergic Pathways: Putative natural treatment modalities for the reduction of drug hunger and relapse.” *IIOAB Letters*; 2011; 1-21.
123. Chen AL, Blum K, Chen TJ, Giordano J, Downs BW, Han D, Barh D, Braverman ER. Correlation of the Taq1 dopamine D2 receptor gene and percent body fat in obese and screened control subjects: A preliminary report. *Food Funct*. 2012; 3(1): 40-8.
124. Blum K, Bailey J, Gonzales A, Oscar-Berman M, Liu Y, Giordano J, Braverman ER, Gold M. Neurogenetics of Reward Deficiency Syndrome (RDS) as a root cause of “Addiction Transfer”: A New Phenomena Common after Bariatric Surgery. *J. Genetic Syndromes & Genetic Therapy*. 2012 (1); S2-001.
125. Morse S, Giordano J, Perrine K, Downs BW, Waite RL, Madigan M, Bailey J, Braverman ER, Damle U, Knopf J, Simpatico T, Moeller M, Barh D, Blum K. Audio Therapy Significantly Attenuates Aberrant Mood in Residential Patient Addiction Treatment: Putative Activation of Dopaminergic Pathways in the Meso-Limbic Reward Circuitry of Humans. *Journal of Addict. Research and Therapy*. 2011; S:3.
126. Blum K, Chen TJH, Fornari F, Lubar J, White N, Lubar J, Schoolfield J, Comings DE, Davis C, Reinking J, Rhoades P, Blum SH, Arcuri V, Kerner M, Savarimuthu S, Mo ES, Palomo T, Stice E, Chen ALH, Bowirrat A, Madigan M, Downs BW, Giordano J, Braverman ER, et al. Generational Association Studies of Dopaminergic Genes in Reward Deficiency Syndrome (RDS) Subjects: Selecting Appropriate Phenotypes for Reward Dependence Behaviors. *International Journal of Environmental Research and Public Health*. 2011; 8(12): 4425-59.
127. Blum K, Giordano J, Morse S, Anderson A, Carbajal J, Waite R, Downs B, Downs J, Madigan M, Barh D, Braverman ER. Hypothesizing Synergy between Acupuncture/Auriculotherapy and Natural Activation of Mesolimbic Dopaminergic

- Pathways: Putative Natural Treatment Modalities for the Reduction of Drug Hunger and Relapse. *HIOAB Letters*. 2011; 1: 8-20.
128. Bowirrat AB, Oscar-Berman M, Bailey J, Braverman ER, Giordano J, Morse S, Downs BW, Waite RL, Fornari F, Blum K. Neuropsychopharmacology and Neurogenetic Aspects of Executive Functioning: Should Reward Gene Polymorphisms Constitute a Diagnostic Tool to Identify Individuals at Risk For Impaired Judgment? *Molecular Neurobiology*. 2012; 45(2): 298-313.
 129. Blum K, Werner T, Carnes S, Carnes P, Bowirrat A, Giordano J, Oscar-Berman M, Gold M, Braverman ER. Sex, Drugs, and Rock 'N' Roll: Hypothesizing Common Mesolimbic Activation as a Function of Reward Gene Polymorphisms. *Journal of Psychoactive Drugs*. 2012; 44(1): 38-55.
 130. Shah Nirav R (NYS Commissioner of Health) and Braverman ER. Measuring Adiposity in Patients: The Utility of Body Mass Index (BMI), Percent Body Fat, and Leptin. *PLoS ONE*. 2012; 7(4): e33308.
 131. Blum K, Chen AL, Giordano J, Borsten J, Chen TJ, Hauser M, Simpatico T, Femino J, Braverman ER, Barh D. The addictive brain: all roads lead to dopamine. *J Psychoactive Drugs*. 2012; 44(2):134-43.
 132. Blum K, Giordano J, Borsten J, Downs BW, Hauser M, Simpatico T, Lohmann R, Braverman ER, Barh D. Translational Research to Uncover Diagnostic & Therapeutic Gene Targets Emerging in a Genomic Era: from Bench to Bedside. *Journal of Genetic Disorders & Genetic Reports*. 2012; 1(1).
 133. Blum K, Tucker D, Graham N, Bailey J, Bowirrat A, Barh D, Braverman ER, Oscar-Berman M, Giordano J, Gold S. Depressed dopamine function in attention deficit/hyperactivity disorder (ADHD): should genotyping of dopaminergic and other gene polymorphisms constitute early diagnosis in children? *Review & Hypothesis* (in press)
 134. Blum K, Femino J, Borsten J, Benya L, Waite RL, Giordano J, Downs BW, Madigan M, Rector C, Braverman ER, Simpatico T, Hauser M, Bailey JA. Neuroadaptagen Amino-Acid Dopaminergic Agonist Facilitates Withdrawal from Long-Term Buprenorphine and Naloxone Combination: Have we found a natural opioid substitution weaning therapeutic agent? *British Journal of Psychiatry*. (Submitted 2012)
 135. Blum K, Miller M, Miller D, Giordano J, Morse S, McCormick L, Downs BW, Waite R, Madigan M, Stuller E, Parker C, Barh D, Yajnik G, Neal D, Braverman ER, Lohmann R, Ross C, Borsten J, Hauser M, Simpatico T. Neurogenetics and Nutrigenomics of Neuro-Nutrient Therapy for Reward Deficiency Syndrome: Clinical Ramifications as a Function of Molecular Neurobiological Mechanisms. *Journal of Addiction Research and Therapy*. 2012; 3(5): 139.
 136. Miller M, Chen A, Stokes S, Silverman S, Bowirrat A, Manka M, Manka D, Miller D, Perrine K, Chen T, Bailey J, Downs BW, Waite RL, Madigan M, Braverman ER, Damle U, Kerner M, Giordano J, Morse S, Oscar-Berman M, Barh D, Blum K. Early Intervention of Intravenous KB220IV- Neuroadaptagen Amino-Acid Therapy (NAAT) [™] Improves Behavioral Outcomes in a Residential Addiction Treatment Program: A Pilot Study. *Journal of Psychoactive Drugs*. 2012. 44(5): 398-409.
 137. Blum, K, Oscar-Berman-M, Giordano J, Simpatico T, Lohman R, Hauser M, Borsten J,

- Braverman ER. Neuropsychiatric Genetics of Happiness, Friendships and Politics: A new era in understanding social interface. *J Genetic Syndromes and Gene Therapy*. 2012; 3(2): e106.
138. Blum K, Bagchi D, Barh D, Giordano J, Morse S, Downs BW, Waite RL, Downs JM, Madigan M, Ross-Coker C, Archer T, Braverman ER. Sugar craving a world epidemic: Is there a nutrigenomic solution? *Journal of Functional Foods*. 2012; 1(9): 310-378.
139. Blum K, Oscar-Berman M, Bowirrat A, Giordano J, Madigan M, Braverman ER, Barh D, Hauser M, Borsten J, Simpatico T. Neuropsychiatric Genetics of Happiness, Friendships, and Politics: Hypothesizing Homophily ("Birds of a Feather Flock Together") as a Function of Reward Gene Polymorphisms. *J Genetic Syndromes and Gene Therapy*. 2012; 3 (112).
140. Blum K, Schoenthaler S, Oscar-Berman M, Giordano J, Alleyn K, Jones S, Hurley K, Madigan M, Braverman E. Drug Abuse Relapse Rates Linked to Level of Education: Hypothesizing Dopamine as a Culprit? *Journal of Addiction Research and Therapy*. 2013; 4(4).
141. Blum K, Han D, Oscar-Berman M, Reinl G, DiNubile N, Madigan M, Bajaj A, William Downs B, Giordano J, Westcott W, Smith L, Braverman E, Dushaj K, Hauser M, Simpatico T, McLaughlin T, Borsten J, Barth D. Iatrogenic Opioid Dependence is Endemic and Legal: Genetic Addiction Risk Score (GARS) with Electrotherapy, A Paradigm Shift in Pain Treatment Options. *Health*. 2013; 5: 14-34.
142. Blum K Oscar-Berman, Femino J, Waite RL, Benya L, Giordano J, Downs BW, Braverman ER, Loehmann R, Dushaj K, Simpatico T, Hauser M, Barh D, McLaughlin T. Withdrawal from Buprenorphine/naloxone and Maintenance with a Natural Dopaminergic Agonist: a Cautionary Note. *J Addiction Research & Therapy*. 2013; 4(2): 146.
143. Braverman ER, Oscar-Berman M, Lohmann R, Kennedy R, Kerner M, Dushaj K, Blum K. Low and Normal IGF-1 Levels in Patients with Chronic Medical Disorders (CMD) is Independent of Anterior Pituitary Hormone Deficiencies: Implications for Treating IGF-1 Abnormal Deficiencies with CMD. *J Genetic Syndromes and Gene Therapy*. 2013; 4(123): pii: 1000123.
144. Braverman ER, Blum K, Damle UJ, Kerner M, Dushaj K, Oscar-Berman M. Evoked Potentials and Neuropsychological Tests Validate Positron Emission Topography (PET) Brain Metabolism in Cognitively Impaired Patients. *PLoS One*. 2013; 8(3): e55398.
145. Barh D, Barve N, Gupta K, Chandra S, Jain N, Tiwari S, Leon-Sicairos N, Canizalez-Roman A, dos Santos AR, Hassan SS, Almeida S, Ramos RT, de Abreu VA, Carneiro AR, Soares Sde C, Castro TL, Miyoshi A, Silva A, Kumar A, Misra AN, Blum K, Braverman ER, Azevedo V. Exoproteome and secretome derived broad spectrum novel drug and vaccine candidates in *Vibrio cholerae* targeted by Piper betel derived compounds. *PLoS One*. 2013; 8(1): e52773.
146. Blum K, Han D, Oscar-Berman M, Reinl G, DiNubile N, Madigan MA, Bajaj A, Downs BW, Giordano J, Westcott W, Smith L, Braverman ER, Dushaj K, Hauser M, Simpatico T, McLaughlin T, Borsten J, Barh D. Iatrogenic Opioid Dependence is Endemic and Legal: Coupling Genetic Addiction Risk Score (GARS) with Electrotherapy as a new paradigm shift in pain relief programs. *Health*. 2013; 5(11A): 16-34.

147. Braverman ER, Oscar-Berman M, Kreuk F, Kerner M, Dushaj K, Li M, Stratton D, Trudesdell C, Blum K. Preliminary Hormonal Correlations in Female Patients as a Function of Somatic and Neurological Symptom Clusters: An Exploratory Development of a Multi-Hormonal Map for Bio-Identical Replacement Therapy (MHRT). *J Genetic Syndromes and Gene Therapy*. 2013; 4(11): pii: 206.
148. Braverman ER, Han D, Oscar-Berman M, Karikh T, Truesdell C, Dushaj K, Kreuk F, Li M, Stratton D, Blum K. Menopause Analytical Hormonal Correlate Outcome Study (MAHCOS) and the Association to Brain Electrophysiology (P300) in a Clinical Setting. *PLoS One*. 2014; 9(9): e105048.
149. Blum K, Schoenthaler S, Oscar-Berman M, Giordano J, Madigan M, Braverman ER, Jones S, Han D. Drug abuse relapse rates linked to level of education: can we repair hypodopaminergic-induced cognitive decline with nutrient therapy? *The Physician and Sports Medicine*. 2014; 42: 1-16.
150. Blum K, Oscar-Berman M, Braverman ER, Gold MS. Raising endogenous brain levels of kynurenic acid may produce anti-reward and enhance suicide ideation. *J Alcohol Drug Depend*. 2014; 2: 151.
151. Waite RL, Allen C, Giordano J, Morse S, Musclemann J, Bowirrat A, Downs BW, Madigan M, Braverman ER, et al. Quantitative electroencephalographic analysis (qEEG) of Neuro-Electro-Adaptive Therapy 12™ [NEAT12] up-regulates cortical potentials in an alcoholic during protracted abstinence: Putative anticraving implication. *Addiction Research and Therapy*. 2014; 5: 1-7.
152. Blum K, Simpatico T, Waite R, Blum S, Dushaj K, Madigan M, Braverman ER, Oscar-Berman M. "Reward" Gene Polymorphisms May Predict High Rates of Injury and Addiction in the Workforce: a nutrient and electrotherapeutic based solution. *Health*. 2014; 6(6): 2261-2285.
153. Blum K, Han D, Madigan M, Giordano J, Lohmann R, Braverman ER. "Cold" X5 Hairlaser™ used to treat male androgenic alopecia and hair growth: an uncontrolled pilot study. *BMC Research Notes*. 2014; 7: 103.
154. Blum K, Braverman ER, Kreuk F, Dushaj K, Li M, Barh D, Oscar-Berman M. Genome wise sequencing compared to candidate gene association studies for predisposition to substance abuse a subset of Reward Deficiency Syndrome (RDS): Are we throwing the baby out with bathwater? *Epidemiology*. 2014; 4(3): 1000158.
155. Blum K, Oscar-Berman M, Badgaiyan R, Braverman ER, Gold MS. Hypothesizing Darkness Induced Alcohol Intake Linked to Dopaminergic Regulation of Brain Function. *Psychology (Irvine)*. 2014; 5(4): 282-288.
156. Blum K, Oscar-Berman M, Waite RL, Braverman ER, Kreuk F, Li M, Dushaj K, Madigan MA, Hauser M, Simpatico T, Barh D. A Multi-Locus Approach to Treating Fibromyalgia by Boosting Dopaminergic Activity in the Meso-Limbic System of the Brain. *J Genetic Syndromes and Gene Therapy*. 2014; 5(1): 213.
157. Blum K, Chen AL, Chen TJH, Prihoda TJ, Waite RL, Williams L, Downs BW, Kerner M, Braverman ER. A Randomized, Double-Blind, Placebo Controlled Investigation of the Anti-Anxiety Effects of Synapatmine Complex™, A Putative Dopaminergic Activator: Hypothesizing a Targeted Psychodermatological Nutraceutical to Reduce Stress and

- Improve Dermatologic Conditions. *J Psychsocial Science*. (In preparation)
158. Blum K, Noble EP, Sheridan PJ, Montgomery A, Ritchie T, Highsmith M, Cohn JB, Wood R, Pritchett DB, Braverman ER. Allelic association of the serotonin 5HT-2A receptor gene in alcoholism: a possible modifying gene. (In preparation)
 159. Blum K, Braverman ER, Gill J, Cull JG, Taub M, Li C, Comings DE, Sherman M, Eisenberg A. Dopamine D2 Receptor gene polymorphisms and alcoholism: appropriate use of "super" normals and "severe" probands. (In preparation)
 160. Blum K, Braverman ER, Wood RE, Gill J, Taub M, Chen THJ. Enhanced frequency of the Taq1A1 allele of the dopamine D2 receptor gene in psychiatrically-ill subjects with comorbid substance use disorder. (In preparation)
 161. Braverman ER, Han D, Oscar-Berman M, Lohmann R, Dushaj K, Damle U, Blum K. Multi-Hormonal Bio-identical Replacement Therapy Map (MHRT) in Menopause: Significant Associations as a Function of Somatic and Neurological Symptom Clusters. *PLoS One*. 2014; 9(9): e105048
 162. Braverman ER, Chen TJH, Waite RL, Bowirrat A, Allen C, Yelandi S, Damle U, Madigan M, Giordano J, Downs BW, Dinubile N, Polamo T, Archer T, Blum K. Neuroquantum Theories of Psychiatric Genetics: Can Weak Forces Induce Epigenetic Influence on Future Genomes. *Journal of Neuroquantology* (In process)
 163. Blum K, Oscar-Berman M, Braverman ER, Febo M, Li M, Gold MS. Enhancing Brain Pegenolone May Protect Cannabis Intoxication but should not be considered as an Anti-Addiction Therapeutic: Hypothesizing Dopaminergic Blockade and Promoting Anti-Reward. *J Reward Defic Syndr*. 2015; 1(1) 20-23

ABSTRACTS AND CONFERENCE PRESENTATIONS

1. Pfeiffer CC, Sohler A, Braverman ER. Oral zinc in normal subjects. *Federation Proceedings*. 1979; 38(3): 680.
2. Pfeiffer CC, Braverman ER. Epochal trace elements and evolution. *Agents and Actions*. 1982; 12(3):412-415.
3. Braverman ER, Lamola S, Pfeiffer CC, Sohler A. Comparison of acute and chronic l-tryptophan loading. *Advances in Clinical Nutrition*. 1985.
4. Braverman ER, Lamola S, Pfeiffer CC. Low plasma tryptophan in depressed out-patients. *Presentation at: 4th World Congress of Biological Psychiatry*; September 1985; Philadelphia, PA.
5. Braverman ER, Weissberg E. The American society of hypertension: Magnesium deficiency and nutritional therapy. *Journal of the American Society of Hypertension*. 1987.
6. Braverman ER. Brain mapping in 100 substance abusers. Presented at: *American Society of Addiction Medicine, 23rd Annual Medical-Scientific Conference*; April 1992.
7. Braverman ER. Modification of P300. Presented at: *American Society of Addiction Medicine, 23rd Annual Medical-Scientific Conference*; April 1992.
8. Blum K, Braverman ER, Wood R, Sheridan P, Comings D. DRD2 A1 Allele and P300 abnormalities in obesity. Presented at: *American Society of Human Genetics*; October 1994; Montreal, Canada.
9. Blum K, Braverman ER, Dinardo M, Wood R, Sheridan P. Prolonged P300 latency in a

- neuropsychiatric population with the D2 dopamine receptor A1 allele. Presented at: American Psychiatric Electrophysiology Association, 2nd annual meeting; May 1994; Philadelphia, PA.
10. DeFrance J, Hymel C, Trachtenberg M, Ginsberg L, Braverman ER, et al. Enkephalinase-inhibition and precursor amino acid loading enhances attention processing and P300 in healthy humans. Presented at: American Psychiatric Electrophysiology Association, 2nd annual meeting; May 1994; Philadelphia, PA.
 11. Blum K, Sheridan P, Wood R, Braverman ER, et al. The D2 dopamine receptor gene as a predictor of "Reward Deficiency Syndrome" (RDS) behavior: Bayes' theorem. Presented at: 149th Annual Meeting of the American Psychiatric Association; May 1996; New York, NY.
 12. Braverman ER, Miller DS, Holland R, Johnson D, Blum K. Myers-Briggs type indicator relationships with the Millon Clinical Multiaxial Inventory Version II. Presented at: 149th Annual Meeting of the American Psychiatric Association; May 1996; New York, NY.
 13. Braverman ER. Amino acids in clinical medicine and neuropsychiatry. Presented at: 149th Annual Meeting of the American Psychiatric Association; May 1996; New York, NY.
 14. Braverman ER, Blum K. Comorbid psychiatric disorders in a holistic health clinic. Presented at: 149th Annual Meeting of the American Psychiatric Association; May 1996; New York, NY.
 15. Braverman ER, Blum K. Comorbid disorders in an obese population. Presented at: 149th Annual Meeting of the American Psychiatric Association; May 1996; New York, NY.
 16. Blum K, Schnautz N, Braverman ER, et al. Association studies of polymorphism of the Dopamine D2 Receptor (DRD2), Dopamine Transporter (DAT1), and the Dopamine Hydroxylase (DxH) genes with impulsive-aggressive-violent and schizoid/avoidant behaviors in adolescent and adult probands. Presented at: 149th Annual Meeting of the American Psychiatric Association; May 1996; New York, NY.
 17. Braverman ER. Real facts on melatonin, tryptophan and amino acids. Presented at: *Los Alamos National Laboratory*; February 1996; Los Alamos, NM.
 18. Blum K, Braverman ER, Cull J, Brenner B, Gill J, Zedar M. Brain Electrophysiological Abnormalities As a Function of the Dopamine D2 Receptor A1 Allele and Comorbid Substance Use Disorder. Presented at: Annual Meeting of American Mental Health; #2132; May, 1996.
 19. Blum K, Kaats G, Davis K, Eisenberg M, Sherman M, Cull J, Woods R, Bucci L, Chen THJ, Braverman ER. Chromium Picolinate induces changes in body composition as a function of TAQ 1 Dopamine D2 Receptor A2 Alleles. Presented at: *American College of Nutrition*; October 1998.
 20. Volkow Nora and Uhl George R. Perspectives on Reward Circuitry, Neurobiology, Genetics and Pathology: Dopamine and Addiction. *Molecular Psychiatry (Vol. 6)*; February 2001. Braverman ER and Smith David as clinical chairpersons at conference on the neurobiology, genetics and pathology of reward systems at Ritz Carlton San Francisco November 12-13, 2000.
 21. Braverman ER, Blum K. P300 latency (An established marker of brain processing speed) correlates with sex hormones and insulin growth factors (IGF-1 and 3). Poster presentation at: ENDO 2005, The Endocrine Society's 87th Annual Meeting; June 2005; San Diego, Ca.
 22. Braverman ER, Blum K. P300 (Latency) event-related potential: An accurate predictor of memory impairment: Hormonal correlates. *Alzheimer's & Dementia*. 2005; 1(S1): S15.
 23. Braverman ER, Blum K. P300 (Latency) event-related potential: An accurate predictor of memory impairment: Hormonal correlates. Presented at: Alzheimer's Conference on Prevention of Dementia; June 2005; Washington, DC.

24. Blum K, Braverman ER, Stice E, et al. Dopamine resistance” in brain reward circuitry as a function of DRD2 gene polymorphisms in Reward Deficiency Syndrome (RDS): Synaptamine complex variant induced “Dopamine Sensitivity” and enhancement of happiness. Presented at: Psychiatric Genetic Meetings; May 2009.
25. Braverman ER, Blum K, Kerner M, et al. Low and normal IGF-1 levels in patients with Chronic Medical Disorders (CMD) is independent of anterior pituitary deficiencies of LH, FSH and TSH: Implications for treating CMD using IGF-1 as a diagnostic marker. Poster Presented at: ENDO 2009, The Endocrine Society’s 91st Annual Meeting; June 2009.
26. Blum K, Stice E, Liu Y, Giordano J, Hon MAC, Morse S, Downs BW, Waite RL, Madigan M, Braverman ER, et al. Dopamine resistance in brain reward circuitry as a function of reward gene polymorphisms in Reward Deficiency Syndrome (RDS): Synaptamine complex variant [KB220]-induced dopamine sensitivity and enhancement of happiness utilizing qEEG. Presented at: XVII World Congress of Psychiatric Genetics; November 2009; San Diego, CA.
27. Braverman ER. DEXA more accurately predicts obesity compared to BMI utilizing American Bariatric Society Criteria for obesity in 1,234 adults in a primary care out-patient facility. *American Association of Clinical Endocrinologists*; April 2010; Boston, MA.
28. Blum K, Stice E, Liu Y, Giordano J, Morse S, Downs BW, Waite RL, Madigan M, Braverman ER, et al. “Dopamine Resistance” in brain circuitry as a function of reward gene polymorphisms in Reward Deficiency Syndrome (RDS): Synaptamine complex variant [KB220 and KB220Z] induced “Dopamine Sensitivity” and anti-craving behavior. Abstract presented at: *Addictions Conference (Elsevier)*; October 28-30, 2010; Washington, D.C.
29. Braverman ER. DEXA more accurately predicts obesity compared to BMI utilizing American Bariatric Society Criteria for obesity in 1,234 adults in a primary care out-patient facility. *American College of Nutrition*; 2010.
30. Blum K, Stice E, Liu Y, Giordano J, Hon MAC, Morse S, Downs BW, Waite RL, Madigan M, Braverman ER, et al. Dopamine resistance in brain reward circuitry as a function of reward gene polymorphisms in Reward Deficiency Syndrome (RDS): Synaptamine complex variant [KB220]-induced “Dopamine Sensitivity” and enhancement of happiness. Presented at the *XIX World Congress of Psychiatric Genetics*, September 10-14, 2011, Washington, D.C.
31. Blum K, Braverman ER, Perrine K, et al. Genetic Addiction Risk Score (GARS) analysis provides diagnostic and therapeutic targets for “dopamine resistance” in Reward Deficiency Syndrome (RDS): Position Emission Topography (PET), Quantitative Electroencephalographic (qEEG) and Functional Magnetic Resonance Imaging (fMRI) techniques reveals nutrigenetic resolution by induction of “Dopamine Sensitivity” in brain reward circuitry. Presented at the *XIX World Congress of Psychiatric Genetics*, September 10-14, 2011, Washington, D.C.
32. Blum K, Liu Y, Rothstein L, Han D, Giordano J, Downs BW, Hausere M, Tian J, Oscar-Berman M, Smolen A, Reisfield GM, Simpatico T, Villapiano A, Braverman ER, Gold M. A role in pain clinics for medication monitoring, genetic addiction risk assessment and KB220Z activation of dopaminergic reward circuitry. 11th Annual Pain Society Meeting.

INVITED PRESENTATIONS, COMMENTARY AND LECTURES

1. Braverman ER. Porphyrin metabolic pathways and their various applications to an understanding

- of some common human disorders. *Proc. 2nd. Int'l Conf. on Hum. Funct*, Biocom. Press: Wichita, 1978.
2. Braverman ER. Biochemistry of zinc. *Proc. 3rd Int'l Conf. on Hum. Funct*. Biocom. Press: Wichita, 1979.
 3. Braverman ER. Amino acids and ketogenic diet," *Proceedings of 2nd International Conference on Diet and Obesity*, Sept. 17, 1986, Israel.
 4. Braverman ER, Weissberg E. Reduction in plasma tyrosine associated with improvement of psychosis. *6th International Catecholamine Symposium*, June 14, 1987.
 5. Blum K, Sheridan PJ, Wood R, Braverman ER. Utilization of Bayes' theorem to estimate the predictive value of the A1 allele of the D2 dopamine receptor gene in compulsive disease." Presented at 17th Annual Meeting of *European Neuroscience Association*, September 1994, Vienna, Austria.
 6. Blum K, Braverman ER, Wood RC, et al. The D2 dopamine receptor gene as a predictors of "Reward Deficiency Syndrome" (RDS). Presented at: *University of Pavia Seminar Series. 1995*. Pavia, Italy.
 7. Blum K, Braverman ER, Cull J, et al. Brain electrophysiological abnormalities as a function of the dopamine D2 receptor A1 allele and comorbid substance use disorder. Presented at: 1996 Annual Meeting of American's Mental Health; May, 1996.
 8. Braverman ER. The comprehensive office based health check-up. Presented at: American Academy of Anti-Aging Medicine, *7th International Conference. December 1999*.
 9. Braverman ER. Human growth hormone replacement therapy: A case gallery of sustained serum levels with injectable supplementation. Poster Presented at: American Academy of Anti-Aging Medicine, *9th International Conference, December 2001*.
 10. Braverman ER. Body fat analysis by DEXA scan: A case review. Poster Presented at: American Academy of Anti-Aging Medicine, *9th International Conference, December 2001*.
 11. Braverman ER, Blum K. Adult growth hormone deficiency: A higher compliance delivery system. Poster Presented at: American Academy of Anti-Aging Medicine, *10th International Conference, December 2002*.
 12. Blum K, Meshkin B, Prihoda, TJ, Downs BW, Waite RL, Braverman ER, et al. DNA-customized genotrim induces significant reduction in weight, appetite, and sugar cravings in D.I.E.T. study: Polymorphic correlates involving five candidate genes in obesity, a clinical subtype of Reward Deficiency Syndrome (RDS). Poster Presented at: Natural Products Association Scientific Session. (Bronze Medal Winner); July 2007; Las Vegas, NV.
 13. Blum K, Williams L, Waite RL, Huntington T, White L, Prihoda T, Braverman ER. First report of Genotrim® to significantly reduce Body Mass Index (BMI) as a function of five candidate (DrD2, MTHFR, 5-HT2a, PPAR-Gamma-2, OB) gene polymorphisms. American Dietetic Association Meeting; 2008.
 14. Braverman ER, Martinez-Pons M, Arcuri V, Meshkin B, Blum K. Prolonged P300 latency is associated with increased parathyroid hormone plasma levels: Subclinical hyperparathyroidism may be antecedent to osteoporosis and dementia. *Presentation. 2009*
 15. Braverman ER, Cognitive decline of aging: Important neuroendocrinological predictors of early cognitive decline in a clinical setting. *Lecture. 2009*.
 16. Braverman ER. Aging and the Pituitary Gland. *The Pituitary Gland in Health and Disease*. Weill

Cornell Medical School. 2013. New York.

17. Braverman ER. The Aftermath of Fukushima: I-131 Exposure and Risks. Today is the Day Benefit Gala. 2013. New York.

LETTERS & REVIEWS

1. Braverman ER. It's so nice to have a man around. *Society for Science & the Public, Science News, Vol 116 No. 12 (Sep 22. 1979)*
2. Braverman ER. Case histories in psychoneuroimmunology. *Psychosomatics, Review*, 1989.
3. Braverman ER. Carl C. Pfeiffer, Ph. D., M. D.: A life of scientific exploration and conquest. *Canadian Schizophrenia Foundation, review*, 1989.
4. Braverman ER. Brain mapping. *Townsend Letter for Doctors* 1991, pp. 254-255.
5. Braverman ER. Addiction: The most critical dimension of nutrition and preventive medicine. *Townsend Letter for Doctors*, 1992.
6. Braverman ER. Brain mapping and electro stimulation: Summary of a presentation. *New York City Health Newsletter*, April 1992.
7. Braverman ER. Electromagnetic pollution: Is there an electromagnetic antidote? *Townsend Letter for Doctors*, August/September 1992; 710-712.
8. Braverman ER, Smith R. CES efficacy evaluation. *Townsend Letter for Doctors*, April 1993; 324-325.
9. Braverman ER. There is hope for depression: Try these holistic alternatives. *Doctor's Forum, Health News and Review*, 1993; 3(4): 12.
10. Reuben C, Chen TJH, Blum SH, Braverman ER, et al. Acupuncture & Auriculartherapy: Valuable natural treatment modalities for treatment for addiction. *Townsend Letters* 269:81-84.
11. Braverman ER, Baker RJ, Loeffke B, Ferrer-Gonzalez G. Combating Radiation Exposure before Disaster Strikes. *Townsend Letter*. 2012. 352: 81-89.

MAGAZINES, NON-ACADEMIC ARTICLES AND CITATIONS

(selected)

Science News

Sperm Fusion. 1979

Science Stats: Fatter than you thought 2012

Health and Nutrition

Psychoneuroimmunology. 1991

Life Extension Magazine

"Eric Braverman, MD: An Innovator of Brain and Body Medicine by Maria Rabat. November 2003.

"Natural Prescriptions for Parkinson's Disease" by Bruce Scali. June 2004.

"Life Extension for The Brain" by Brice Scali. March 2004.

"Nutrients for Treating Obsessive-Compulsive

Collier's

The Addiction Gene: Why millions are inherently at risk? 2012

People Magazine

"Celeb Diet Secrets," June 7, 2004

Smart Money Magazine

"Finding Your Fountain of Youth," May 11, 2005

US Weekly

Dr. Braverman comments on photographs of Lindsay Lohan and Nicole Richie and their dramatic weight loss, May 18, 2005

Vogue

Disorder” September 2004.
“Hormone Replacement Therapy”; October 2004.
“Discusses Epidemic of Silent Disease” August 2009
“Stop Silent Disease Before they Strike” 2010
“Obesity Epidemic in America Found Significantly Worse Than Previously Believe” In the News, 2012
“Life Extension Funded Study Shows Obesity Epidemic Much Worse Than What Doctors Claim” 2012

Explore!

Cognitive impairment begins at 30: How to avoid dementia. 2010
FSH and LH elevations are associated with dementia. 2010
Mild head trauma: A method for detection in primary care and its critical importance. 2010

TELEVISION APPEARANCES *(selected)*

ABC/ABCFam

Eyewitness News (12/12/2001, 02/11/2002, 7/10/2002)
ABC News Now (2008)
700 Club (2007)

BBC World News

Nightly News (4/4/2012)

CBS

WCBS-TV (11/2/2001, 11/6/2001)
Channel 2 News, Live at Five (7/10/2002)

NBC/CNBC/MSNBC

The Today’s Show (2007)
MSNBC-TV Live (7/10/2002, 7/20/2002)
Scarborough Report(interviewed about drugs) (5/9/2005)
Nightly News with Brian Williams (4/2/2012)

FOX/FOX News Channel

Good Day New York (9/27/2001, 11/5/2001, 1/31/2002)

“The Science of Looking Good,” January 2007
New Yorker
“Precision-Tune Your Hypochondria,” January 22-29 2007
Elle
“One Will Make You Smaller,” February 2007
Men’s Vogue
“Liver Worst,” September 2007
Townsend Letter
“Combating Radiation Before Disaster Strikes” November 2012

WPIX

News at 10 (7/10/2002)
Tyra Banks Show (10/24/2007)

PBS

Get Healthy Now with Gary Null (1999)

CNN

Dazzle Unlimited (7/1998)
Larry King Live (2/16/2000)
Talk Back Live (3/5/2002)
CNN News (Interviewed about Ephedra) (5/19/2005)
Wolf Blitzer Reports (discussed Atkins Diet), August 1, 2005

NY1

Call in Show (11/8/2001, 11/27/2001, 11/30/2001, 12/5/2001, 12/6/2001,12/10/2001, 12/11/2001, 12/12/2001)

Other Television Shows

Bermuda National Television (2/1998,

The O'Reilly Factor (2/28/2002, 6/14/2004)	5/1998)
Fox News Channel (6/19/2004)	Bay TV News (San Francisco, CA)
The Big Show with John Gibson (5/19/2005)	(11/13/2000)
Your World with Neil Cavuto, (discussed	News 12 New Jersey (11/22/2001)
Atkins diet) (8/1/2005)	CN8-TV- Real Life with Mary Amoroso
UPN	(8/11/2004, 8/12/2004)
UPN 9 News – (discussed Atkins Diet)	TBN-Regular Host (1995-1997)
(8/1/2005)	

RADIO SHOW APPEARANCES *(selected)*

Weekly Radio Show

WABC- NY, NY Sundays 2pm-4pm 1986-1987, Total Health
 77WABC Sundays 12pm-1pm, Present
 WOR-NY, NY Every Sunday 8pm-9pm 1988-1996, May 2003-2012
 WEVD,AM-NY, NY Sundays 9pm-10pm 1997- 2002
 WNEW,FM- NY, NY Sundays 9pm-10pm 2002- 2003
 WWRL,AM- NY, NY Mondays 2pm-3pm and Tuesdays 11am-11:30am 2003- Present

Guest Radio Appearances

KFNX , Phoenix, AZ	KTRC - Sante Fe, NM	KCRS , Odessa, TX
Thinking Outside the Box 7/04	Mysteries of the Mind 5/03	The Morning Show 6/04
9KNOT , Prescott, AZ	WOR-AM- NY, NY	KFIZ , Milwaukee, WI
Health Talk 4/03	Carlton Fredericks Show	Backstage Live 7/04
KNST , Tucson, AZ	ADD Action Group 11/01	<u>Internet/ Satellite Radio</u>
An Ounce of Prevention with	WCBS-AM- NY, NY 10/01	America's Health Network
Dr. Dan 7/04	The Osgood File 11/01	Ask the Family Doctor,
KSWB , SanDiego, CA	WCBS-FM- NY, NY	12/98
Someone You Should Know	Steve O'Brien Show 6/04	Associate Press Radio
3/03	Stan Taylor Show 6/04	Ephedra 4/05
WGUN , Atlanta, GA	WMCA- NY, NY	Cable Radio Network
Temple of Health	Pat McCann Show	Coast to Coast Live 8/04
WOKA , Douglas, GA	WBBR- NY, NY9/01,10/01,	Healthylife.net,
The Book Club Radio Show	WVXU , Cincinnati, OH	Lights on with Nancy Lee 8/04
5/03	On Your Feet For Life 8/04	Internet Radio
Stan Taylor Show	WDVT - Philadelphia, PA	Coping with Caregiving 3/03
KBUR , Burlington, IA	WIP - Philadelphia, PA	Sirius Radio Network, CA,
The Rod Cary Show 7/04	Healthline	OR
WROK , Rockford, IL	WPTT - Pittsburg, PA	Healthy Family6/04
The Riley O'Neal Show 4/03	The Jerry Bowyer Show 8/04	Voice America.com, Topanga
Langer Broadcasting , Boston,	WZYX , Cowan, TN	CA
MA,	Sound Off 4/03	Waking Up in America 4/03

Science and Technology 4/03

WBIX, Quincy, MA

The Frankie Boyer Show 6/04